List of Contract Research Companies in Germany - 25

Aix Scientifics is a Contract Research Organisation that specializes in planning, implementing, and evaluating clinical research for pharmaceutical products and medical devices.

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

ARTES Biotechnology is a globally working, well established and reliabletechnology provider for recombinant protein production. They develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.

Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world's leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

Bicoll is an expert in bioactive plant-derived small molecules with outstanding expertise in high-tech natural product chemistry and validated experience in medicinal chemistry. Currently Bicoll focuses on two main fields such as neurodegenerative disorders (primarily, epilepsy) and longevity. In both of the fields it develops own preclinical candidates.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

Contract Manufacturing & Analytical

Celonic is a "Pure Play" Biologics Contract Development Manufacturing Organization (CDMO). Celonic's mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, "next generation" bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic. Due to the expansion of the company, Celonic is looking for committed and qualified employees. Our job is to make a difference!

ChemCon GmbH - Your Good Manufacturing Partner! ChemCon is a contract development and manufacturing organization (CDMO) located in Freiburg, Germany. We manufacture drug substances (injectable, ophthalmic, oral, topic grade) and ultra-pure chemicals to your specifications. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds, polymers, and highly potent or controlled substances. ChemCon’s facilities are optimized for the production of small to medium quantities (g to multi 100 kg per year). This is particularly interesting if you are sourcing APIs for clinical trials or commercial applications (i.e., orphan diseases, oncology, or emergency care) with a low annual demand. We also manufacture excipients, provocation substances, dietary trace elements, diagnostics, delivery agents, or reference standards. Your project will be under one roof from synthesis & process development/establishment all the way to commercial cGMP manufacturing, including full documentation, quality control and regulatory support. We also offer external analytical services, independent from production services. ChemCon looks back on an outstanding inspection history by both the FDA and European health authorities. Impressum: ChemCon GmbH, Engesserstr. 4b, 79108 Freiburg i.Br. Phone.: +49 (0)761-5597-0; E-Mail: Info@chemcon.com CEO/President: Dr. Raphael Vogler Commercial register: HRB 5973 Court of registration: Freiburg VAT Reg. No: DE812753447

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

CRELUX, part of WuXi AppTec’s Research Service Division, is a global provider of structure based drug discovery solutions. We have been delivering customized and integrated services in drug discovery, X-ray crystallography, protein supply, biophysical analysis and fragment screening, to support small and large molecule, as well as biopharmaceutical drug discovery, for more than a decade. Our mission is to enable our clients to perform their work faster, more efficiently and more successfully. Integrating the comprehensive portfolio of services offered by our parent company WuXi AppTec, CRELUX offers a unique opportunity for our collaborators to accelerate discovery activities. Imprint: CRELUX GmbH Am KIopferspitz 19a 82152 Martinsried Germany www.crelux.com crelux_info@wuxiapptec.com VAT: DE242220245 Amtsgericht München HRB 165552 Managing Directors: Dr. Alex Satz, Dr. Thomas Meins

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI's focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

IDT Biologika is your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting humans worldwide! We are committed to your development and manufacturing needs from the early stages of process development to clinical trial materials and commercial manufacturing: • Process Development • Clinical & Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply: • FDA, EMA, ANVISA standards European and North American Footprint IDT Biologika is headquartered in Germany (Dessau-Rosslau and Magdeburg in Saxony-Anhalt). Here we operate one of Europe's premier integrated biopharmaceutical facilities for end-to-end services: • Process Development • Clinical Phases I-III • Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Commercial Manufacturing • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services Our North American facility is in Rockville, Maryland. The site has a long history of contract manufacturing and state-of-the-art technologies used to develop and manufacture clinical trial materials for phases I–II: • Process Development • Clinical-Scale Drug Substance (Viral Vaccines, Viral Vectors for Cell & Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization • Packaging & Storage • Analytical Service

MLM Medical Labs is a leading specialty and central laboratory with comprehensive research services and diagnostic capabilities in Europe and the United States. Offering standard and fully customizable analytical and logistics services across a variety of therapeutic areas, we add value at every stage of the drug development process, from nonclinical and preclinical through phase IV clinical trials. Each therapeutic area is supplemented extensively by different models and batteries of in vitro and ex vivo analyses, offering answers to your therapeutics’ effect on over 900+ parameters while accelerating your research programs. With our strong reputation for scientific expertise, passionate approach to customer care, and adherence to quality data, we empower clients ranging from emerging biotech to Top Ten Global Pharma companies to reach confident clinical decisions that ultimately serve to improve patient lives.

NMI TT Pharmaservices is a Contract Research Organization dedicated to provide experts services to customers in Pharma, Biotech and Academia. Our business is focused on high-quality services and R&D support, for preclinical drug discovery & development, drug mode of action studies, predictive toxicology, safety pharmacology, and biomarker screening. Our main competences are - Protein Profiling Services - Custom Cell Services - Electrophysiology Services NMI TT GmbH, a privately-held company founded in 2002, is a subsidiary of the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation, with operations in Reutlingen and Berlin, Germany.

Founded in Europe with more than 40 years of experience, NUVISAN is a fully integrated contract research and development, and manufacturing organization (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. NUVISAN, a formerly independent, family-owned contract research organization (CRO), has grown significantly over the years and has expanded its services and capabilities to meet the changing needs of its clients. Operating under the name NUVISAN since 2010, ALS Limited, the global leader in testing, acquired NUVISAN on April 1, 2024, forming the most advanced drug discovery and development organization and providing solutions across continents. We are pleased to offer the following portfolio of services: • Target Identification and Validation • Target-to-Lead • Lead-to-Candidate • Preclinical • Clinical Our services can be provided as stand-alone or integrated solutions and can be customized to your project. To find out more, visit us: www.nuvisan.com or send an email: hello@nuvisan.com.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

ProBioGen is a renowned contract development and manufacturing organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With 30 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end. Watch & learn more: https://youtu.be/vtEgrEVfj70

Transforming proteins into pioneering drugs ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as "bio-betters" are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing. We offer: • predictive formulation analytics • formulation development including in-depth protein analytics • lyophilization process development and optimization • lyophilization in dual chamber prefilled syringe • development of liposomal formulations, producible by simple stirring • manufacturing of preclinical study material • technology-transfer including scale-up to GMP-manufacturer We deliver: • optimized formulations for biopharmaceuticals • tailored manufacturing processes and transfer to GMP manufacturing • development reports ready for submission to the authorities for registration

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients. With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

We turn active ingredients into medicine. As one of the leading pharmaceutical service providers for the aseptic manufacture of injectable medicines, we are a global player – and a family business. Together with our 6,000 employees, we help improve the lives of people around the world. We combine tradition and innovation in a job that has meaning. Ravensburg is where our roots are. We make a significant contribution to reliably supplying patients with medicines from our state-of-the-art production sites in Europe and the United States. We work hand in hand with pharmaceutical and biotechnology companies of all sizes, accompanying them on their journey to help those who are affected with their treatment of cancer, multiple sclerosis, and other diseases – from active ingredient development all the way to its delivery in people. With success comes responsibility. Teamwork, openness, and commitment: These qualities are important to us. At Vetter, we are sustainably helping to shape the future. We fully support personal and professional development – to build a strong team in which everyone can develop their skills, and in which every contribution counts. And for those who rely on us. Find out more about our company at www.vetter-pharma.com/ Privacy Notice: https://www.vetter-pharma.com/en/privacy-notice Imprint: https://www.vetter-pharma.com/en/imprint

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.